Ajanta Pharma, a specialty focused pharma formulation company in India, has clocked strong performance during the year ended March 2012. Its consolidated net profit has taken quantum jump of 52 per cent and reached at Rs.77.27 crore from Rs.50.71 crore in the previous year. Its consolidated net sales also registered strong growth of 35 per cent to Rs.671.38 crore from Rs.497.40 crore. The earning per share worked out to Rs.65.99 as against Rs.43.31 in the previous year.

The Board of Directors has recommended handsome dividend of Rs.7.50 per share of Rs.10 each for the year 2011-12. The company decided to split its equity share of Rs.10 each into 2 equity shares of Rs.5 each. Recently, Ajanta scrip touched to its yearly high level at Rs.571 on BSE.

Ajanta continues to aggressively execute the strategy of specialty player in the branded generic market in India and Rest of the World. In the regulated market, it continues to build its ANDA portfolio in USA. The company filed another 2 ANDA during the fourth quarter in US taking the total ANDA's under review with the US FDA to 7. The company will commence its sales of 2 ANDAs from first quarter of FY13.

It is gaining grounds in domestic market with improved ranking, enhancing depth in export ROW markets and making the beginning in USA with its first product being available in the US market from coming quarter onwards. The company has leading brands in the therapeutic segment of ophthalmology, dermatology and cardiology. It exports its products to more than 25 countries and established strong brand equity in these markets.